TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype

Abstract Presence of TP53 mutations has been associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL), although this has remained controversial. The TP53 codon 72 polymorphism has shown negative impact on cancer survival, but this has not been analyzed in DLBCL. Furthermore, the MDM2...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia research 2009-01, Vol.33 (1), p.60-66
Main Authors: Zainuddin, Norafiza, Berglund, Mattias, Wanders, Alkwin, Ren, Zhi-Ping, Amini, Rose-Marie, Lindell, Monica, Kanduri, Meena, Roos, Göran, Rosenquist, Richard, Enblad, Gunilla
Format: Article
Language:English
Subjects:
Clinical Genetics
Diffuse large B-cell lymphoma
Germinal center subtype
Hematology, Oncology and Palliative Medicine
Humans
Klinisk genetik
Lymphoma, B-Cell - genetics
Lymphoma, Non-Hodgkin - genetics
MDM2 SNP309
Medical Genetics
MEDICIN
Medicin och hälsovetenskap
MEDICINE
Medicinsk genetik
Molecular Genetics
Molekylär genetik
Mutation
Oncology
Onkologi
Survival
Survival Analysis
TP53 codon 72 polymorphism
TP53 mutation
Tumor Suppressor Protein p53 - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Presence of TP53 mutations has been associated with poor prognosis in diffuse large B-cell lymphoma (DLBCL), although this has remained controversial. The TP53 codon 72 polymorphism has shown negative impact on cancer survival, but this has not been analyzed in DLBCL. Furthermore, the MDM2 SNP309 has been associated with earlier age of onset in DLBCL. Here, we investigated the clinical impact of TP53 mutations, MDM2 SNP309 and TP53 codon 72 polymorphisms on survival in DLBCL of germinal center (GC) and non-GC subtypes. Thirteen of the 102 (12.7%) patients displayed TP53 mutations. Overall, TP53 mutations had a significant effect on lymphoma-specific survival (LSS, P = 0.009) and progression-free survival (PFS, P = 0.028). In particular, inferior survival was observed in TP53 -mutated DLBCLs of GC subtype (LSS, P = 0.002 and PFS, P = 0.006). Neither MDM2 SNP309 nor the TP53 codon 72 polymorphism had an impact on age of onset or survival. Altogether, our data suggests that TP53 mutations are associated with poor outcome in GC-DLBCL patients.
ISSN:0145-2126
1873-5835
1873-5835
DOI:10.1016/j.leukres.2008.06.022